Many animals such as mice and rabbits have similar DNA structures to humans. Thus, scientists often test products on them before using on people. However, animal testing leads to many consequences
Since the outbreak of COVID-19 in December 2019, this disease has been continuing to develop, and expand strongly, not only leading to major crises in health care but also affecting economies and security around the world. Recently, the emergence of the Delta strain originating from India can spread 40-60% more easily than the old variant – Alpha. Therefore, it is more urgent than ever to localize outbreaks and quickly detect positive COVID-19 cases. Senix Group started researching about COVID tests and realized that each test has strengths and weaknesses that need to be addressed.
At the moment, the testing method which gives the highest accuracy is RT-PCR. However, RT-PCR requires a system of specialized devices, and people who perform the test must have a high technical capacity. In addition, the cost of an RT-PCR test kit is expensive which makes it difficult to be widely executed for community testing. Therefore, a simpler, more time-saving, and cost-effective method plays an important role in assisting medical professionals to prevent the spread of virus.
The CareStart™ COVID-19 Antigen Rapid Test is an In Vitro rapid diagnostic test used for the qualitative detection of SARS-CoV-2 antigen (Ag) in nasopharyngeal swab samples collected directly from patients with clinical symptoms or no clinical symptoms but with epidemiological factors suspected of being associated with COVID-19. The product effectively supports the screening process of classifying patients with symptoms and epidemiological factors suspected of COVID-19 infection.
This method has a sensitivity of 93.8% and a specificity of 99%. The remarkable advantage is that the CareStart™ test process is not too complicated and only takes 10 minutes to give the test results. In addition, the cost of this optimal method is about 30% lower compared to similar products on the market. CareStart™ COVID-19 Antigen is produced at the world’s leading factory Access Bio in the United States and is being used widely by many countries such as the United States, Australia, and Germany.
Due to the devastating impact of this pandemic, it is necessary to come up with immediate measures to detect the outbreaks so that the spread does not expand widely. CareStart™ rapid test is surpassing current methods in Vietnam not only in terms of cost but also in accuracy and result turnaround time. It proves that this method can do a good job. In rapid community testing to support diagnosis, early localization, control and avoid the virus spreading to the community.